EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates initiates its coverage of CardioVascular
BioTherapeutics (OTCBB:CVBT) with a Neutral rating. The 19-page report
by Dutton Associates senior analyst Richard W. West, CFA is available at www.jmdutton.com
as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and
other leading financial portals. CardioVascular BioTherapeutics is a
biopharmaceutical company currently focused on developing new drugs for
the treatment of cardiovascular diseases where the growth of new blood
vessels may improve the outcome for patients with these diseases. The
Company's drug candidates are designed to facilitate the growth of new
blood vessels in the heart and other tissues and organs that have an
impaired vascular system.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 28 senior analysts are primarily CFAs, and have
expertise in many industries. Dutton & Associates provides continuing
analyst coverage of 140 enrolled companies, and its research, estimates,
and ratings are carried in all the major databases serving institutions
and online investors.
The current cost of enrollment in our one-year continuing research
program is US $39,500 prepaid for 4 Research Reports, typically
published quarterly, and requisite Research Notes. Dutton & Associates
received $35,000 from the Company for 4 Research Reports with coverage
commencing on 09/26/06. The Firm does not accept any equity
compensation. Our principals and analysts are prohibited from owning or
trading in securities of covered companies. The views expressed in this
research report accurately reflect the analyst's personal views about
the subject securities or issuer. Neither the analyst's compensation nor
the compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please read
full disclosures and analyst background at www.jmdutton.com
before investing.
